Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,721,688
  • Shares Outstanding, K 115,472
  • Annual Sales, $ 159,200 K
  • Annual Income, $ 129,120 K
  • 36-Month Beta 1.48
  • Price/Sales 8.00
  • Price/Cash Flow 32.39
  • Price/Book 6.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.17
  • Number of Estimates 2
  • High Estimate 0.21
  • Low Estimate 0.13
  • Prior Year 0.17
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.70 +27.69%
on 12/24/18
16.08 -7.09%
on 01/16/19
+0.30 (+2.05%)
since 12/18/18
3-Month
11.21 +33.27%
on 10/30/18
19.48 -23.31%
on 12/12/18
+2.40 (+19.14%)
since 10/18/18
52-Week
11.21 +33.27%
on 10/30/18
25.96 -42.45%
on 01/29/18
-8.64 (-36.64%)
since 01/18/18

Most Recent Stories

More News
Is the Options Market Predicting a Spike in Corcept (CORT) Stock?

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

CORT : 14.94 (+0.20%)
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing's Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym and...

CORT : 14.94 (+0.20%)
Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics

NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday's trading session. MYOS RENS shares soared after news of...

CORT : 14.94 (+0.20%)
MYOS : 1.79 (+2.87%)
VSI : 4.89 (+1.87%)
Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA),...

WLTW : 158.66 (+1.08%)
CORT : 14.94 (+0.20%)
TSLA : 302.26 (-12.97%)
PDLI : 3.12 (-1.89%)
NDSN : 128.28 (+2.57%)
PAYC : 136.24 (+3.04%)
Corcept Initiates Phase III Study for Cushing's Syndrome

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

CORT : 14.94 (+0.20%)
CELG : 86.27 (-0.37%)
LLY : 116.59 (-2.16%)
PFE : 42.53 (+0.14%)
Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing's Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 14.94 (+0.20%)
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates

Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.

CORT : 14.94 (+0.20%)
CELG : 86.27 (-0.37%)
PFE : 42.53 (+0.14%)
BMY : 50.12 (+1.05%)
Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CORT : 14.94 (+0.20%)
Corcept: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported third-quarter profit of $17.8 million.

CORT : 14.94 (+0.20%)
Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 14.94 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 15.40
1st Resistance Point 15.17
Last Price 14.94
1st Support Level 14.74
2nd Support Level 14.54

See More

52-Week High 25.96
Fibonacci 61.8% 20.33
Fibonacci 50% 18.58
Fibonacci 38.2% 16.84
Last Price 14.94
52-Week Low 11.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar